

CSL Limited
45 Poplar Road Parkville
Victoria 3052 Australia

T +613 9389 1911
F +613 9389 1434
www.csl.com.au



ASX Announcement

For immediate release

5 May 2021

Presentation at Macquarie Australia Conference 2021

Please find attached a presentation to be given by Dr Paul McKenzie at the Macquarie Australia Conference 2021.

Authorised by
Fiona Mead
Company Secretary

For further information, please contact:

Investors:

Bernard Ronchi
Senior Manager, Investor Relations
CSL Limited
T: +613 9389 3470
Email: bernard.ronchi@csl.com.au

Media:

Christina Hickie
Senior Manager, Communications
CSL Limited
T: +613 9389 3425 M: +61 429 609 762
Email: christina.hickie@csl.com.au



CSL Limited
Macquarie Conference
5 May, 2021



Paul McKenzie, PhD
Chief Operating Officer

Legal Notice

FORWARD LOOKING STATEMENTS

The materials in this presentation speak only as of the date of these materials and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.


Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks

Except where otherwise noted, brand names designated by a TM or [®] throughout this presentation are trademarks either owned by and/or licensed to CSL.

Values and 2030 Strategy

Strategic Overview



Core Values



We deliver on our promise to patients



We turn innovative thinking into solutions



We walk the talk



We are stronger together



We take pride in our results



Over the next decade, Operations has a critical role to play in helping CSL ensure that we can meet demand for our products and continue to deliver on our promise to patients and health systems.



Changes in Operations have provided direction for new ways of working and behaviors required to achieve CSL's 2030 Strategy



What We are Focused on Achieving



Engaged and inclusive culture delivering top-tier results **for safety, quality, reliability and innovation**



End-to-end operations visibility and control by **partnering with the other key partners** in delivering for our patients



Global network mindset including both internal and external capabilities and capacities to **ensure scalability**



An organization which embraces **modernization** to allow us to **stabilize and scale**

We have created a streamlined, de-layered, global Operations organization designed to scale and grow to deliver for our patients



AN INTEGRATED, GLOBAL OPERATIONS NETWORK



DECREASED LAYERS ACROSS THE NETWORK



INTRODUCED NEW & EXPANDED CAPABILITIES



ACCELERATED DIGITAL TRANSFORMATION

Our Vision for Operations

“Operations enables CSL’s promise to patients and public health in the 2030 Strategy by developing a **continuously learning team** of CSL employees and partners that has a global mindset and is focused on efficiently delivering top-tier results for **safety, quality, reliability** and **innovation.**”



Safety



Quality



Reliability



Innovation



People

BHAGS

Establish an injury-free and environmentally responsible workplace driven by individual accountability and behaviour.

Provide donor-to-patient quality that ensures we are always right first time and constantly inspection-ready.

Enhance our customer-focused, demand-driven supply chain.

Become the most agile responsive and efficient E2E supply chain, delivering profitable business results.

Be a continuously learning organization that embraces diversity and inclusion and provides robust development opportunities to our people to deliver on our promise.

Operations Management of COVID-19 Challenges

- Plasma centers and manufacturing sites kept open during the pandemic to maintain supply of lifesaving medicines and influenza vaccines
- Took actions to prevent product and supply chain disruptions
- Development of strict protocols to ensure the safety of our employees and donors
- Provided support for COVID-19 vaccines and supply of MF59®



Plasma Collections

Continue to grow plasma collection network



25 new centers opening in FY21 the United States

“
ALL CENTERS REMAIN OPEN
”




300+ centers:

- ✓ 284 United States
- ✓ 9 Germany
- ✓ 3 Hungary
- ✓ 5 China



Plan to open **40** new centers in FY22



Plasma Collections

COVID-19 Impact



Challenge

- Plasma collections adversely impacted
- FY20 plasma collection volume down
- Additional collection costs incurred



Mitigation

- Collection centers designated “essential critical infrastructure”
- Adjustments to U.S. donor compensation
- Call-back program for first-time, lapsed and temporarily deferred donors
- Comprehensive campaign to raise awareness of the opportunity and need for plasma donation



Protecting Staff and Donors

Actions

- Pre-assessment of potential donors
- Plasma-designed social distancing
- Enhanced cleaning & disinfectant procedures
- ‘Safe passage’ letters provided to staff, donors and key vendors

Seqirus



Operating Highlights

- Delivery of a record-setting >100 million doses for the Northern Hemisphere 20/21 influenza campaign
- Ongoing shift to differentiated products
- Real-world evidence continues to demonstrate the potential for improved effectiveness of FLUCELVAX[®] & FLUAD[®]

Looking Forward

- Planning underway for construction of new cell-culture vaccine facility in Melbourne
- Fill & finish expansion:
 - Liverpool operational from Northern Hemisphere 21/22
 - Holly Springs operational from Northern Hemisphere 22/23





CSL™

Working for Patients &
Human Health Around
the World

Seqirus
A CSL COMPANY